| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | GRIK3 |
| Uniprot No | Q13003 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-919aa |
| 氨基酸序列 | MTAPWRRLRSLVWEYWAGLLVCAFWIPDSRGMPHVIRIGGIFEYADGPNAQVMNAEEHAFRFSANIINRNRTLLPNTTLTYDIQRIHFHDSFEATKKACDQLALGVVAIFGPSQGSCTNAVQSICNALEVPHIQLRWKHHPLDNKDTFYVNLYPDYASLSHAILDLVQYLKWRSATVVYDDSTGLIRLQELIMAPSRYNIRLKIRQLPIDSDDSRPLLKEMKRGREFRIIFDCSHTMAAQILKQAMAMGMMTEYYHFIFTTLDLYALDLEPYRYSGVNLTGFRILNVDNPHVSAIVEKWSMERLQAAPRSESGLLDGVMMTDAALLYDAVHIVSVCYQRAPQMTVNSLQCHRHKAWRFGGRFMNFIKEAQWEGLTGRIVFNKTSGLRTDFDLDIISLKEDGLEKVGVWSPADGLNITEVAKGRGPNVTDSLTNRSLIVTTVLEEPFVMFRKSDRTLYGNDRFEGYCIDLLKELAHILGFSYEIRLVEDGKYGAQDDKGQWNGMVKELIDHKADLAVAPLTITHVREKAIDFSKPFMTLGVSILYRKPNGTNPSVFSFLNPLSPDIWMYVLLAYLGVSCVLFVIARFSPYEWYDAHPCNPGSEVVENNFTLLNSFWFGMGSLMQQGSELMPKALSTRIIGGIWWFFTLIIISSYTANLAAFLTVERMESPIDSADDLAKQTKIEYGAVKDGATMTFFKKSKISTFEKMWAFMSSKPSALVKNNEEGIQRALTADYALLMESTTIEYVTQRNCNLTQIGGLIDSKGYGIGTPMGSPYRDKITIAILQLQEEDKLHIMKEKWWRGSGCPEEENKEASALGIQKIGGIFIVLAAGLVLSVLVAVGEFVYKLRKTAEREQRSFCSTVADEIRFSLTCQRRVKHKPQPPMMVKTDAVINMHTFNDRRLPGKDSMACSTSLAPVFP |
| 分子量 | 130.4 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下为模拟生成的关于重组人GRIK3蛋白的参考文献示例(仅供学术写作参考)：
---
1. **"Expression and functional characterization of recombinant human GRIK3 in E. coli"**
*Zhang et al., 2020. Protein Expr. Purif.*
摘要：该研究优化了人源GRIK3蛋白在大肠杆菌中的重组表达条件，利用His标签纯化获得高纯度蛋白，并通过电生理实验验证其与谷氨酸的配体结合活性。
2. **"Cryo-EM structure of the human GRIK3 kainate receptor"**
*Smith et al., 2021. Nat. Struct. Mol. Biol.*
摘要：首次解析了重组人GRIK3红藻氨酸受体的冷冻电镜结构，揭示了其跨膜结构域动态变化机制，为靶向神经疾病的药物设计提供结构基础。
3. **"GRIK3 genetic variants and synaptic protein interactions in schizophrenia"**
*Johnson et al., 2019. Mol. Psychiatry*
摘要：通过重组GRIK3蛋白与突触后蛋白的体外结合实验，证明其罕见变异可能破坏神经递质通路，提示其作为精神分裂症生物标志物的潜力。
4. **"Pharmacological profiling of recombinant human GRIK3 receptors"**
*Lee et al., 2018. J. Biol. Chem.*
摘要：系统评估了重组GRIK3蛋白对多种激动剂/拮抗剂的响应特性，发现其选择性激活可调节海马神经元突触可塑性。
---
**说明**：以上文献信息为模拟生成，实际引用需通过PubMed/Web of Science等平台核实。建议以关键词“recombinant human GRIK3”、“GLUK3 protein”或“kainate receptor expression”检索最新研究。
Recombinant human GRIK3 protein is a genetically engineered form of the GluK3 subunit, a key component of kainate-type glutamate receptors (KARs) in the central nervous system. These receptors, part of the ionotropic glutamate receptor family, mediate excitatory neurotransmission and synaptic plasticity by binding glutamate, the primary neurotransmitter in the brain. The GRIK3 gene encodes the GluK3 subunit, which assembles with other subunits (e.g., GluK1 or GluK2) to form heterotetrameric ligand-gated ion channels. These channels regulate neuronal excitability, synaptic development, and network activity. Dysregulation of GRIK3 expression or function has been linked to neuropsychiatric disorders, including schizophrenia, bipolar disorder, and Alzheimer’s disease, highlighting its potential as a therapeutic target.
Recombinant GRIK3 is typically produced in mammalian or insect cell systems to ensure proper post-translational modifications and membrane protein folding. It enables detailed studies of receptor structure, ligand-binding kinetics, and downstream signaling mechanisms. Researchers use this protein in electrophysiological assays, calcium imaging, and high-throughput drug screening to identify modulators for neurological therapies. Its production also supports structural biology efforts (e.g., cryo-EM) to resolve receptor architecture and ligand interaction sites. By providing a pure, functional form of GluK3. recombinant GRIK3 accelerates research into KAR biology and disease-related mechanisms.
×
